NASDAQ$MAZE
Maze Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
Maze Therapeutics reported Q1 2026 with $20M revenue, net loss of $24.2M, and diluted loss per share of $0.45.
For the period ended 2026-03-31, Maze Therapeutics reported $20M revenue. License revenue $20.0M. Net loss $24.2M improved vs. $32.8M prior year. Genetic medicine platform; revenue from license agreements.
- License revenue $20.0M.
- Net loss $24.2M improved vs. $32.8M prior year.
- R&D $34.1M.
Headline financials
Revenue & EPS history
Maze Therapeutics Inc · Revenue · Quarterly
$20M
Forward guidance
Genetic medicine platform; revenue from license agreements.
Tailwinds
- License revenue in quarter.
- Loss narrowing YoY.
Headwinds
- R&D $34.1M.
- Pipeline clinical risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 2 quarterly earnings reports · overlaid with Q1 2026
+0.3%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+38.8%
Avg return
30 days after
67%
2 / 3 earnings
Positive
+2.0%
Q2 2025
Best reaction
-2.1%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.9% | +0.4% | -5.6% | |
| Q3 2025 | -2.1% | +6.6% | +37.8% | |
| Q2 2025 | +2.0% | +0.2% | +84.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro